Aviragen Therapeutics Announces Inducement Grant for New Employee
July 01 2016 - 04:01PM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota
Pharmaceuticals, Inc.), a pharmaceutical company that is developing
the next generation of antivirals, announced today that the
compensation committee of the Company’s Board of Directors granted
to Jonas Niaura, Vice President of Business Development and
Strategy, an option to purchase an aggregate of 200,000 shares of
the Company’s common stock with a per share exercise price of
$1.40, the closing price on June 30, 2016. The stock option has a
ten-year term and vests over a period of three years, with
one-third vesting on the first anniversary of the grant date and
one-third vesting on each of the two succeeding anniversaries. The
option is subject to the terms and conditions of the Company's 2007
Omnibus Equity and Incentive Plan and the stock option agreement
pursuant to which the option is granted.
The stock option was granted as an inducement material to the
new employee’s entering into employment with Aviragen
Therapeutics in accordance with NASDAQ Listing Rule
5635(c)(4).
About Aviragen Therapeutics, Inc.Aviragen
Therapeutics is focused on the discovery and development of the
next generation of direct-acting antivirals to treat infections
that have limited therapeutic options and affect a significant
number of patients globally. The Company has three product
candidates in active clinical development: These include
vapendavir, an oral treatment for human rhinovirus upper (HRV)
respiratory infections in moderate-to-severe asthmatics currently
being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral
fusion protein inhibitor that has received Fast Track designation
by the U.S. FDA, in Phase 2 development for the treatment and
prevention of respiratory syncytial virus (RSV) infections; and
BTA074, a topical antiviral treatment in Phase 2 development for
condyloma caused by human papillomavirus types 6 & 11. For
additional information about the Company, please visit
www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2023 to Mar 2024